Nanobiotix S.A. (NBTX) |
|
3.45 0.1 (2.99%)
|
03-17 10:40 |
|
Open: |
3.45 |
Pre. Close: |
3.35 |
|
High:
|
3.45 |
Low:
|
3.36 |
|
Volume:
|
114 |
Market Cap:
|
120(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:13 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 4.56 One year: 4.95 |
| Support: |
Support1: 3.35 Support2: 2.79 |
| Resistance: |
Resistance1: 3.9 Resistance2: 4.24 |
| Pivot: |
3.55 |
| Moving Average: |
MA(5): 3.53 MA(20): 3.59
MA(100): 3.87 MA(250): 4.33 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2  |
| Stochastic oscillator: |
%K(14,3): 8.9 %D(3): 19.7 |
| RSI: |
RSI(14): 41.9 |
| 52-week: |
High: 7.53 Low: 2.31 |
| Average Vol(K): |
3-Month: 1 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NBTX ] has closed above bottom band by 26.0%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.46 - 3.48 |
3.48 - 3.49 |
|
Low:
|
3.31 - 3.34 |
3.34 - 3.35 |
|
Close:
|
3.42 - 3.45 |
3.45 - 3.48 |
|
Company Description |
|
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France. |
Headline News |
Wed, 15 Feb 2023
SERA stock jumps as study for preterm birth test succeeds ... - Seeking Alpha
Tue, 14 Feb 2023
Voting Rights and Shares Capital of the Company - GlobeNewswire
Thu, 02 Feb 2023
AKBA stock jumps after FDA nod for GSK kidney disease therapy ... - Seeking Alpha
Tue, 03 Jan 2023
Sesen Bio investors plan to vote against Carisma merger(NASDAQ ... - Seeking Alpha
Wed, 28 Dec 2022
AKBA stock on watch after licensing deal for ferric citrate product ... - Seeking Alpha
Mon, 26 Dec 2022
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
35 (M) |
|
% Held by Insiders
|
2.977e+007 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
3 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.76e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
795.8 |
|
Return on Equity (ttm)
|
-29.2 |
|
Qtrly Rev. Growth
|
2.66e+006 |
|
Gross Profit (p.s.)
|
0.44 |
|
Sales Per Share
|
-110.39 |
|
EBITDA (p.s.)
|
1.47222e+006 |
|
Qtrly Earnings Growth
|
-1.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-32 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
5.21 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1840 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
